1st Quarter - Amendment

NOVARTIS for NOVARTIS

Firm
Client
Income
—
Expenses
$3,093,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report Apr 20, 2016 $3,150,000 Replaced
1st Quarter - Amendment (this page) Apr 20, 2016 $3,093,000 Yes

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Biosimilars Medicare Part D Drug Pricing Part B

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
SHAWN O'NEAIL —
CANDICE PHIPPS —
WENDY P SUSSMAN —
JASON BENJAMIN VAN PELT —

Contacted: Food & Drug Administration (FDA); U.S. Agency for International Development (USAID); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; State, Dept of (DOS); Commerce, Dept of (DOC); White House Office; Office of Management & Budget (OMB); SENATE; U.S. Trade Representative (USTR)

Budget/Appropriations BUD

FDA Appropriations funding for Generic Drugs Certified Importer Program (CIP) FY 2016 Labor HHS Appropriations Bill Reconciliation Gx Drug Labeling

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
SHAWN O'NEAIL —
WENDY P SUSSMAN —
JASON BENJAMIN VAN PELT —

Contacted: U.S. Trade Representative (USTR); SENATE; Food & Drug Administration (FDA); U.S. Agency for International Development (USAID); White House Office; Commerce, Dept of (DOC); State, Dept of (DOS); Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

ACA Pharmaceutical Industry Fee Exclusions R&D Tax Credit Anti-Inversion Tax H.R.3618 - Orphan Drug Fairness Act S.1906 - Orphan Drug Fairness Act Medical Device Tax Repeal & Suspension

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
SHAWN O'NEAIL —
CANDICE PHIPPS —
JASON BENJAMIN VAN PELT —

Contacted: U.S. Agency for International Development (USAID); U.S. Trade Representative (USTR); SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Commerce, Dept of (DOC); State, Dept of (DOS); Office of Management & Budget (OMB); White House Office; Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 3618 (114th), S. 1906 (114th)

Trade (domestic/foreign) TRD

Free Trade Agreements: - Intellectual Property and Transparency Provisions - Free Trade Agreements Access to Medicines Issues Global Health Issues India, China and Canada IP and market Access Issues Trans-Pacific Partnership FTA Sub-standards Medicines Quality of Medicines Global Intellectual Property Issues Including: - Trade Promotion Authority - Trans-pacific Partnership - Trans Atlantic Trade and Investment Partnership International Market Access and Intellectual Property Issues Biopharmaceutical Innovation Policies

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
LEO A FARBER —
SARAH HALLER —
JASON BENJAMIN VAN PELT —

Contacted: White House Office; SENATE; Commerce, Dept of (DOC); State, Dept of (DOS); U.S. Agency for International Development (USAID); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Office of Management & Budget (OMB); U.S. Trade Representative (USTR)

Copyright/Patent/Trademark CPT

HR3116 MODDERN Cures Act of 2013 S.632 STRONG Patents Act of 2015 HR.9 Innovation Act S.1137 PATENT Act Data Exclusivity Trade Secrets Intellectual Property Biopharmaceutical Innovation Policy Issues Biologics Data Protection Issues Patient Litigation Reform and Issues Related to Post Grant Proceedings at PTO S.1890 Defend Trade Secrets Act of 2016 H.R.3326 Defend Trade Secrets Act of 2015

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
SHAWN O'NEAIL —
CANDICE PHIPPS —
JASON BENJAMIN VAN PELT —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; State, Dept of (DOS); White House Office; U.S. Trade Representative (USTR); Office of Management & Budget (OMB); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); U.S. Agency for International Development (USAID)

Bills named: H.R. 3326 (114th), H.R. 3116 (114th), S. 632 (114th), S. 1137 (114th), H.R. 9 (114th), S. 1890 (114th)

Health Issues HCR

S.2041 - Promoting Life-Saving New Therapies for Neonates Act of 2015 S.481 - Improving Regulatory Transparency for New Medical Therapies Act H.R.2841 - Fair Access for Safe and Timely Generics Act of 2015 H.R.6 - 21st Century Cures Act Gene Therapy Personalized Medicine Section 9008 of Patient Protection and Affordable Care Act FSA/HSA - Support reinstating coverage of OTC products HR351/S351 - Medicine Decisions Act of 2011 (IPAB) 340B Drug Discount Program Dual Eligibles Program DQSA Implementation (Track & Trace) Certified Importer Program MDUFA (Medical Device User Fee Act) Implementation Drug Importation Reimbursement for medical devices GMP related to manufacturing sites Biosimilars PDUFA Low-income Subsidy in Part D REMS FCLCA Value of Medicines Drug Cost/Pricing Biosimilars Reimbursement Generic Drugs Medicaid FDA Regulations of Lab Developed Tests (LDT) Reimbursement for LDTs 2015 Omnibus Appropriations bill Part B Demo Regrow Act IPAB Generic Drug Labeling H.R.4784 Lower Drug Costs through Competition Act S.2615 Increasing Competition in Pharmaceuticals Act

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
SARAH HALLER —
SHAWN O'NEAIL —
CANDICE PHIPPS —
WENDY P SUSSMAN —
JASON BENJAMIN VAN PELT —

Contacted: Food & Drug Administration (FDA); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); State, Dept of (DOS); White House Office; Office of Management & Budget (OMB); U.S. Agency for International Development (USAID); SENATE; U.S. Trade Representative (USTR)

Bills named: H.R. 351 (114th), H.R. 6 (114th), H.R. 4784 (114th), S. 481 (114th), S. 2615 (114th), S. 2041 (114th), H.R. 2841 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.